Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established ...
Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...
Baylor College of Medicine will be a site for a new multi-institution project aimed at investigating preclinical drug safety assessments. The project, known as DATAMAP, the Digital Acceleration of ...
Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.
Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing NEW YORK, Dec. 8, ...
Agentic AI could reshape drug development. In this interview, Dr. Claudio D’Ambrosio discusses how agentic AI can identify novel drug compounds, improve trial design, and reduce operational ...
Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor ...
Broadcast Retirement Network's Jeffrey Snyder discusses the use of Artificial Intelligence in the creation of new drug with Early-Stage Biotech Scientist Andrew R. Snyder, PhD. Jeffrey Snyder, ...
ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, today announced the ...
TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results